Literature DB >> 2938025

Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen.

R Raisman, R Cash, Y Agid.   

Abstract

The density of high-affinity 3H-imipramine and 3H-paroxetine binding sites (two serotonin-uptake blockers) was decreased in the putamen of parkinsonian patients. The correlation between serotonin levels and the number of 3H-imipramine and 3H-paroxetine binding sites suggests that they are located on serotoninergic nerve terminals and could be used to study serotoninergic innervation in the human brain. Since imipramine and paroxetine are powerful antidepressants, these results furthermore suggest that decreased serotoninergic transmission may be implicated in the pathophysiology of depression in Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2938025     DOI： 10.1212/wnl.36.4.556

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  12 in total

1.  The state of the serotonin transporter protein in the platelets of patients with somatoform [correction of somatiform] disorders.

Authors:  A R Belous; S Ramamoorthy; R D Blakely; M I Factor; A M Dupin; A B Katasonov; R H Lozier; A G Beniashvili; M A Morozova; O S Brusov
Journal:  Neurosci Behav Physiol       Date:  2001 Mar-Apr

Review 2.  The serotonin 5-HT1D receptor: a progress review.

Authors:  C Waeber; P Schoeffter; D Hoyer; J M Palacios
Journal:  Neurochem Res       Date:  1990-06       Impact factor: 3.996

Review 3.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 5.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

6.  Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study.

Authors:  Kjell Erlandsson; Tharani Sivananthan; Dominic Lui; Andrea Spezzi; Caroline E Townsend; Song Mu; Richard Lucas; Steven Warrington; Peter J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

7.  Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls.

Authors:  G Faludi; K Tekes; L Tóthfalusi
Journal:  J Psychiatry Neurosci       Date:  1994-03       Impact factor: 6.186

Review 8.  Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.

Authors:  S M Holliday; G L Plosker
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

9.  Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.

Authors:  Li Li; Guozhen Qiu; Shengyuan Ding; Fu-Ming Zhou
Journal:  Brain Res       Date:  2012-11-15       Impact factor: 3.252

10.  Simultaneous [99mTc]TRODAT-1 and [123I]ADAM brain SPECT in nonhuman primates.

Authors:  Kuo-Hsing Ma; Jong-Kang Lee; San-Yuan Huang; Chin-Bin Yeh; Yi-Chun Shen; Lie-Hang Shen; Chia-Chieh Chen; Ren-Shyan Liu; Jiang-Chuan Liu; Wen-Sheng Huang
Journal:  Mol Imaging Biol       Date:  2009-02-19       Impact factor: 3.488
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.